Profound, Telix Ink PSMA-PET Deal for TULSA-PRO

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) said on 9 October 2026 that it entered a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX), pairing Telix's PSMA-targeting PET imaging agents, Gozellix and Illuccix, with Profound's MRI-guided TULSA-PRO prostate ablation platform. The companies did not disclose financial terms, exclusivity provisions or a contract duration. Profound's stated aim is increased access to urologists through what it called a strong strategic partner, plus a framework for evidence-based patient selection and treatment planning. Profound is also developing PSMA-PET–MR image-fusion for a planned future release of its Treatment Delivery Console software.

Context — Why This Matters for Prostate Care Economics

The agreement arrives as Profound tries to widen the clinical utility and adoption of TULSA-PRO, its flagship interventional MRI platform. Profound describes TULSA-PRO as cleared by the FDA for transurethral ultrasound ablation of prostate tissue and cleared or approved in Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the UAE.

The company frames the deal as a market-development tool rather than a sales contract. Chief executive Arun Menawat said the agreement strengthens a relationship with an important strategic participant in the prostate cancer ecosystem and increases access to urologists across the U.S. and internationally.

Profound's own reasoning runs through patient selection. PSMA-PET imaging may identify distant metastases or disease beyond the prostate that would not otherwise be readily detected, which the company believes could enable more precise patient stratification and potentially broaden the population considered for the TULSA Procedure.

That matters because TULSA-PRO competes for patients against surgery and radiation, the two modalities the company says carry typical side-effect risks including urinary incontinence and erectile dysfunction. A diagnostic gate that screens out inappropriate candidates protects both outcomes and the procedure's reputation.

Telix's side of the logic is educational. Kevin Richardson, chief executive of Telix Precision Medicine, said clinical education is essential to helping physicians understand how PSMA-PET imaging can inform patient selection and treatment planning across minimally invasive and image-guided approaches.

Data — What the Agreement Actually Specifies

Planned initiatives include participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, plus development of educational content, clinical case studies and best-practice materials. No budget, revenue split, minimum volume commitment or timeline was disclosed.

Profound's technical claim is the sharpest measurable element. Chief technology officer Mathieu Burtnyk said approximately 85% of prostate cancers are multifocal, involving two or more distinct index or satellite lesions in different areas of the prostate, while approximately 15% are unifocal with a single tumor site, citing a 2009 pathology paper.

Item	Detail
Agreement type	Co-education, non-exclusive language absent
Telix products named	Gozellix, Illuccix (Ga-68 gozetotide kits)
Profound product named	TULSA-PRO
Financial terms	Not disclosed
Planned software	PSMA-PET–MR image fusion in future TDC release

Burtnyk also said molecular imaging may help identify the roughly 15-25% of patients who are candidates for focal ablation, as well as certain higher-risk patients who may remain suitable for whole-gland ablation. That 15-25% band is the commercial hinge: it is the slice of the prostate population Profound believes PSMA-PET could route toward its platform.

Profound's contrast is technical. It says the planned fusion would incorporate Telix's diagnostic PSMA-PET data into treatment planning using real-time intra-operative MR images, which it describes as much more precise than competitor approaches that register old diagnostic data to real-time ultrasound.

Analysis — Who Is Exposed and What Could Go Wrong

The agreement touches two listed healthcare names. Profound trades on Nasdaq and the TSX; Telix trades on the ASX and Nasdaq. Both are commercial-stage companies, meaning the market can price execution rather than approval probability alone.

Second-order effects run through the prostate cancer diagnostic and treatment chain. If PSMA-PET becomes a routine pre-treatment gate, the imaging agent volume accrues to Telix's diagnostics franchise, anchored by Illuccix, which Telix says is commercially available in 22 countries including the U.S., and Gozellix, approved by the FDA for prostate imaging. Profound's benefit is indirect: better-selected patients entering TULSA-PRO centers.

The stated economic argument is that incorporating PSMA-PET capabilities within TULSA-PRO centers could strengthen their clinical and economic value proposition, including through more informed treatment decisions and potentially enhanced return on investment. That is a center-level ROI claim, not a company-level revenue forecast.

The limitation is that education agreements do not guarantee procedure volume. Profound did not disclose whether the arrangement is exclusive, whether either party pays the other, or what proportion of TULSA-PRO centers already use Telix imaging agents. Without those figures, the agreement's near-term contribution to revenue is unquantifiable from the disclosure.

A counter-argument also sits in the imaging data itself. Detecting disease beyond the prostate is designed to exclude patients from TULSA-PRO, not enroll them. The company's thesis is that net patient flow rises because appropriate candidates are identified earlier and referral confidence improves.

Positioning is event-driven. Profound's shareholder base is exposed to adoption news and console software milestones; Telix's is exposed to radiopharmaceutical volume and its late-stage therapeutic pipeline, which includes TLX591-Tx in prostate cancer, TLX101-Tx in recurrent glioblastoma and TLX250-Tx in kidney cancer.

Outlook — What to Watch Next

The next visible checkpoints are the planned educational activities: society meetings, key opinion leader programs, summits, speaker programs and webinars, plus the educational content, case studies and best-practice materials the companies intend to develop. None carries a date in the disclosure.

The more consequential catalyst is the PSMA-PET–MR image-fusion capability planned for a future Treatment Delivery Console release. Profound calls it a planned future release and gives no timing, so the software's arrival is the milestone that would convert the agreement from education into a workflow feature.

Watch also for evidence that TULSA-PRO centers adopt Telix's PSMA-PET agents, since the company's ROI argument depends on that pairing. Profound did not disclose current penetration.

No price levels are named in the report, and none are asserted here. Investors tracking either name should treat procedure volumes, console software releases and center-level adoption as the measurable variables, not the announcement itself.

Frequently Asked Questions

What does the Profound and Telix agreement actually cover?

It covers education, not product supply. The two companies intend to jointly educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on how Telix's PSMA-PET imaging fits with Profound's MRI-guided TULSA-PRO platform. Planned activities include society meeting participation, key opinion leader programs, summits, speaker programs, webinars, case studies and best-practice materials. No product purchase, distribution or revenue-sharing terms were disclosed.

What is PSMA-PET and why does it matter for TULSA-PRO?

PSMA-PET is a molecular imaging technique that targets prostate-specific membrane antigen. Profound believes it can detect distant metastases or disease beyond the prostate that might otherwise go undetected, which could help physicians decide whether a patient remains a suitable candidate for the TULSA Procedure. It is a selection filter, not a therapy, and the company expects it to support more precise patient stratification over time.

How many prostate cancers are multifocal, and why does that matter?

Profound's chief technology officer said approximately 85% of prostate cancers are multifocal, involving two or more distinct lesions in different prostate areas, while approximately 15% are unifocal with a single tumor site. The company argues TULSA-PRO's advantage is supporting customized regional ablation plans spanning whole-gland, focal and intermediate approaches, and that imaging may identify the 15-25% of patients suited to focal ablation.

Bottom Line

Profound and Telix are funding education, not sales, so the deal's value depends on whether PSMA-PET changes referral behavior.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.